Symbol Therapeutics
Modified Protein for Treatment of Autoimmune Diseases
Company Overview
Snapshot
Founded in November 2021, Symbol Therapeutics operates with 1–10 employees. The company has raised $3M across one funding round from two investors. In September 2022, Symbol Therapeutics secured seed funding from RMGP Biopharma Investment Fund and FutuRx.
Business overview
Symbol Therapeutics is a drug discovery company focused on developing a novel immunoregulatory therapeutic protein. This modified form of endogenous Semaphorin3A is designed for the treatment of systemic lupus erythematosus and other autoimmune diseases. The company's proprietary modified protein aims to activate anti-inflammatory regulatory mechanisms to restore normal immune homeostasis, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What is Symbol Therapeutics' primary focus?
- Symbol Therapeutics is a drug discovery company developing a novel immunoregulatory therapeutic protein, a modified form of endogenous Semaphorin3A, for the treatment of systemic lupus erythematosus and other autoimmune diseases.
- When was Symbol Therapeutics founded?
- Symbol Therapeutics was founded in November 2021.
- What is the company's current operational status?
- Symbol Therapeutics is currently non-active, having ceased to operate in November 2025.
- What is the core technology behind Symbol Therapeutics' approach?
- The company's core technology involves a proprietary modified protein designed to activate anti-inflammatory regulatory mechanisms, thereby restoring normal immune homeostasis.
- Which investors participated in Symbol Therapeutics' seed funding round?
- In September 2022, Symbol Therapeutics secured seed funding from RMGP Biopharma Investment Fund and FutuRx.